Taken together, KCTD10 suppresses lung cancer progression and immune escape via the β-catenin/PD-L1 axis, and its expression is tightly regulated by METTL14-dependent m6A modification, highlighting its potential as a therapeutic target. Here, KCTD10 is linked to lung cancer.